U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H67NO13.HI.H2O
Molecular Weight 879.8545
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERYTHROMYCIN HYDRIODIDE MONOHYDRATE

SMILES

O.I.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

InChIKey=HEJPDPJSITZJAW-INORWZNNSA-N
InChI=1S/C37H67NO13.HI.H2O/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;;/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;1H;1H2/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;;/m1../s1

HIDE SMILES / InChI
Molecular Formula HI
Molecular Weight 127.91241
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C37H67NO13
Molecular Weight 733.9268
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 18 / 18
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/7023159 | http://www.polfa-tarchomin.com.pl/wp-content/uploads/2013/07/Ulotka_Davercin-tabletki-powlekane-250mg.pdf | https://www.doz.pl/leki/p2615-Davercin_tabletki

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved pharmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Information about erythromycin ethylsuccinate is unavailable.

Originator

Eli Lilly
239
Curator's Comment: H. Bojarska-Dahlig and W. Slawinski, Rocz. Chern. 46, 2211 (1972)

Approval Year

1952
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1076
 14.0 nM [Kd]
Inhibitor
8504
Binding Agent
1076
 14.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8583
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8583
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8583
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8583
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8583
Davercin

Approved Use

For the topical treatment of acne vulgaris
Curative
Approved
8583
Davercin

Approved Use

For the topical treatment of pneumonia
Curative
Approved
8583
Davercin

Approved Use

Indicated for the treatment of bacterial endocarditis
Curative
Approved
8583
Davercin

Approved Use

Unknown
Curative
Approved
8583
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Curative
Approved
8583
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Curative
Approved
8583
E.E.S

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Curative
Approved
8583
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Curative
Approved
8583
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.44 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.18 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.99 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
250 mg 4 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.62 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
250 mg 4 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1161.5 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1386.1 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.1 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.1 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3544.7 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4096.7 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.48 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.31 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
5 g 1 times / day single, oral
Studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: single
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
healthy, 12 years
Health Status: healthy
Age Group: 12 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
Other AEs: Pancreatitis...
Other AEs:
Pancreatitis
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
5.3 g 1 times / day single, oral
Studied dose
Dose: 5.3 g, 1 times / day
Route: oral
Route: single
Dose: 5.3 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
healthy, 15 years
Health Status: healthy
Age Group: 15 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
Other AEs: Pancreatitis...
Other AEs:
Pancreatitis
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (2.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Disc. AE: Nausea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Nausea (14.6%)
Abdominal pain (4.9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
Health Status: unhealthy
Age Group: mean age 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Disc. AE: Epigastralgia, Nausea...
AEs leading to
discontinuation/dose reduction:
Epigastralgia (grade 2-3, 2.5%)
Nausea (grade 3, 3.3%)
Vomiting (grade 2, 0.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Other AEs: Akathisia, Diarrhea...
Other AEs:
Akathisia (below serious, 1 patient)
Diarrhea (below serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
AEs

AEs

AESignificanceDosePopulation
Pancreatitis
5 g 1 times / day single, oral
Studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: single
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
healthy, 12 years
Health Status: healthy
Age Group: 12 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
Pancreatitis
5.3 g 1 times / day single, oral
Studied dose
Dose: 5.3 g, 1 times / day
Route: oral
Route: single
Dose: 5.3 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
healthy, 15 years
Health Status: healthy
Age Group: 15 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
Vomiting 2.8%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Nausea 14.6%
Disc. AE
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Abdominal pain 4.9%
Disc. AE
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Vomiting grade 2, 0.8%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
Health Status: unhealthy
Age Group: mean age 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Epigastralgia grade 2-3, 2.5%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
Health Status: unhealthy
Age Group: mean age 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Nausea grade 3, 3.3%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
Health Status: unhealthy
Age Group: mean age 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Akathisia below serious, 1 patient
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Diarrhea below serious, 1 patient
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

P-gp
1741

OATP1B1
1079

OATP1B3
961
CYP3A
220

OAT2
125
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 likely
CYP3A4
2633
 moderate [IC50 9.9 uM]
yes (co-administration study)
Comment: Erythromycin increased mean Cmax value of simvastatin 3.4 fold and AUC0-24 value 6.2 fold; coadministered erythromycin has been reported to increase AUCs of simvastatin, triazolam, and midazolam 6.2-, 3.6-, and 3.8-fold, respectively; A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin;
Page: 10.0
OATP1B1
1095
 yes [IC50 217 uM]
P-gp
1932
 yes [IC50 22.7 uM]
OATP1B3
970
 yes [IC50 34 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OAT2
125
 yes
CYP3A
220
 yes
likely (co-administration study)
Comment: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug
Page: 9.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0126
http://www.3bsc.com/index/pro_info.php?id=19482
Aaron Chemicals
AR0039Z1
http://www.aaronchem.com/114-07-8
abcr GmbH
AB251852
http://www.abcr.com/shop/en/AB251852
Achemtek
0104-008056
http://www.achemtek.com/114-07-8
Acorn PharmaTech
ACN-048190
http://www.acornpharmatech.com/
Acros Organics
AC227330050
https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227330050
Acros Organics
AC227330250
https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227330250
Acros Organics
AC227331000
https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227331000
Acros Organics
AC343880050
https://www.fishersci.com/shop/products/erythromycin-eur-ph-acros-organics/AC343880050
Acros Organics
AC343880250
https://www.fishersci.com/shop/products/erythromycin-eur-ph-acros-organics-1/AC343880250
AEchem Scientific Corp., USA
AE061269
https://www.aechemsc.com/info_products/AE061269.php
AHH Chemical co.,ltd
API-1112
http://www.ahhchemical.com/product/API-1112.html
Alfa Chemistry
114-07-8
https://www.alfa-chemistry.com/erythromycin-cas-114-07-8-item-289674.htm
Alfa Chemistry
AP114078
https://reagents.alfa-chemistry.com/product/erythromycin-cas-114-07-8-1997.html
Alfa Chemistry
AP114078-A
https://reagents.alfa-chemistry.com/product/erythromycin-standard-solution-cas-114-07-8-1998.html
Alfa Chemistry
AP114078-B
https://reagents.alfa-chemistry.com/product/erythromycin-cas-114-07-8-1999.html
ApexBio Technology
B1939
http://www.apexbt.com/erythromycin.html
Aurora Fine Chemicals LLC
A13.139.732
http://online.aurorafinechemicals.com/info?ID=A13.139.732
Avantor Inc
200006-440
https://us.vwr.com/store/product/18600820/erythromycin
Avantor Inc
97061-220
https://us.vwr.com/store/catalog/product.jsp?catalog_number=97061-220
BioCrick
BCC4778
http://www.biocrick.com/Erythromycin-BCC4778.html
BioSynth
E-3250
https://www.biosynth.com/products/biochemistry/culture-media-additives/products/E-3250.html
BLD Pharm
BD17733
http://www.bldpharm.com/products/114-07-8.html
Boerchem
BC205124
http://www.boerchem.com/?product_34527.html
Chem Scene
CS-2168
http://www.chemscene.com/114-07-8.html
Chemchart
cc-erythromycin
http://chemchart.com/erythromycin-detail.html
ChemMol
30102455
http://www.chemmol.com/chemmol/30102455.html
ChemMol
30102582
http://www.chemmol.com/chemmol/30102582.html
Chemspace
CSSB00000053730
https://chem-space.com/CSSB00000053730
CSNpharm
CSN12503
https://www.csnpharm.com/products/erythromycin.html
DC Chemicals
DC7409
http://www.dcchemicals.com/product_show-E_Mycin.html
eNovation Chemicals
D488558
https://www.enovationchem.com/ProductDetails.asp?ProductID=D488558
eNovation Chemicals
D565961
https://enovationchem.com/ProductDetails.asp?ProductID=D565961
eNovation Chemicals
D916215
https://www.enovationchem.com/ProductDetails.asp?ProductID=D916215
Glentham Life Sciences
GA1145
http://www.glentham.com/products/product/GA1145/
Hairui
HR130758
http://www.hairuichem.com/en/product/114-07-8.html
iChemical
EBD28902
http://www.ichemical.com/products/114-07-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network
LN00237041
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00237041
LGC Standards
DRE-A13203490AL-100
https://www.lgcstandards.com/US/en/p/DRE-A13203490AL-100
LGC Standards
DRE-C13203490
https://www.lgcstandards.com/US/en/p/DRE-C13203490
mcule
MCULE-4566208867
https://mcule.com/MCULE-4566208867/
MedChem Express
HY-B0220
https://www.medchemexpress.com/Erythromycin.html
MuseChem
A000680
https://www.musechem.com/product/A000680.html
MuseChem
R007004
https://www.musechem.com/product/R007004.html
Oakwood
94643
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=79817&ExtHyperLink=1
OChem
657
http://www.ocheminc.com/index.php?act=psearch&pid=114E078
Parchem
10930
http://www.parchem.com/chemical-supplier-distributor/Erythromycines-000930.aspx
Parchem
16967
http://www.parchem.com/chemical-supplier-distributor/Erythromycin-006967.aspx
Shanghai Tauto Biotech Co., Ltd
E-0288
http://www.tautobiotech.com/BRM/eProductShow.asp?ArticleID=370
Sigma-Aldrich
1242000_USP
https://www.sigmaaldrich.com/catalog/product/usp/1242000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
45674_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/45674?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
45703_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/45703?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
BP794_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/bp794?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
E0774_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/e0774?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S527402
http://www.smolecule.com/products/s527402
TCI (Tokyo Chemical Industry)
E0751
http://www.tcichemicals.com/eshop/en/us/commodity/E0751/index.html
THE BioTek
bt-267660
https://www.thebiotek.com/product/inhibitors/bt-267660
VladaChem
VL272699-25G
https://www.vladachem.com/product.php?products=114-07-8
Yuhao Chemical
HL1432
http://www.chemyuhao.com/114-07-8.html
PubMed

PubMed

TitleDatePubMed
On the CH...Cu agostic interaction: chiral copper(II) compounds with ephedrine and pseudoephedrine derivatives.
2005-08-14
Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).
2005-08
On-line identification of sugarcane (Saccharum officinarum L.) methoxyflavones by liquid chromatography-UV detection using post-column derivatization and liquid chromatography-mass spectrometry.
2005-07-29
Molecular recognition of sialic acid end groups by phenylboronates.
2005-06-20
[Biological effects of a natural alkyl-diacylglyceride preparation in rats with experimental cardioangiopathy].
2005-06-07
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005-06
Desensitization of the human motilin receptor by motilides.
2005-06
Cytotoxicity of neolignans identified in Saururus chinensis towards human cancer cell lines.
2005-05
Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]).
2005-05
The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine.
2005-05
In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.
2005-04
Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?
2005-04
Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.
2005-01
High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line.
2005-01
Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia.
2005
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
2004-12
Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro.
2004-11
Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
2004-11
Enantiomeric separation of racemic neolignans on chiralcel OD and determination of their absolute configuration with online circular dichroism.
2004-10
Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats.
2004-09
Bitterness evaluation of medicines for pediatric use by a taste sensor.
2004-08
Delayed Gastric Emptying in Functional Dyspepsia.
2004-08
Highly diastereoselective reductive coupling of 2-bromo-2,3,3,3-tetrafluoropropanamide with aldehydes promoted by triphenylphosphine-titanium(IV) isopropoxide. An efficient route to the synthesis of erythro-alpha-fluoro-alpha-(trifluoromethyl)-beta-hydroxy amides.
2004-07-23
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
2004-07
Mechanism of beta-silyl diacyl peroxide decomposition: a mild and stereoselective synthesis of beta-silyl esters.
2004-05-28
Straightforward synthesis of sphinganines via a serine-derived Weinreb amide.
2004-04-30
[Usefulness of oral exfoliative cytology for the diagnosis of oral squamous dysplasia and carcinoma].
2004-03
Effect of particle size on mixing degree in dispensation.
2004-03
Effect of mixing method on the mixing degree during the preparation of triturations.
2004-03
Conformational study of a guaiacyl beta-O-4 lignin model compound by NMR. Examination of intramolecular hydrogen bonding interactions and conformational flexibility in solution.
2004-03
Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids.
2004-02-23
[3 + 2] Cycloreversion of bicyclo[m.3.0]alkan-3-on-2-yl-1-oxonium ylides to alkenyloxyketenes. Stereospecific aspect.
2004-02-20
Local mechanisms underlying the regulatory effect of Kropanol on hemopoiesis during paradoxical sleep deprivation.
2004-02
Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis.
2004-02
Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.
2003-12-01
Ratio of erythro and threo forms of beta-O-4 structures in tension wood lignin.
2003-11
A novel three-component reaction catalyzed by dirhodium(II) acetate: decomposition of phenyldiazoacetate with arylamine and imine for highly diastereoselective synthesis of 1,2-diamines.
2003-10-16
[Hantavirus-induced acute renal failure. A case report].
2003-10
erythro-1-Naphthyl-1-(2-piperidyl)methanol: synthesis, resolution, NMR relative configuration, and VCD absolute configuration.
2003-09-19
The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids.
2003-09-01
Isolation and antimicrobial susceptibility of Aeromonas salmonicida in rainbow trout (Oncorhynchus mykiss) in turkey hatchery farms.
2003-09
Effects of amphotericin B and caspofungin on histamine expression.
2003-08
Effect of erythromycin on contractile response of uterine smooth muscle strips in non-pregnant rats.
2003-07-15
Massive venlafaxine overdose resulted in a false positive Abbott AxSYM urine immunoassay for phencyclidine.
2003
Mixed chimerism of erythro- and megakaryopoiesis following allogeneic bone marrow transplantation.
2003
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992-09
The in-vitro activity of two new quinolones: rufloxacin and MF 961.
1992-06
[Bacteriostatic activity and killing curves of eight antibiotics against seven strains of penicillin G-resistant pneumococci].
1992-05
[In vitro activity of sparfloxacin against mycoplasmas].
1992-05
Drug-induced gallbladder disease. Incidence, aetiology and management.
1992-01-01
Patents

Patents

03963579
26
06794372
28
EP0119431 A1
26
JP2000229993A
26
JP2000516450A
29
JP2001521945A
47
JP2002121197A
26
JP2002241392A
26
JP2002511777A
420
JP2002520071A
27
JP2002521468A
37
JP2004323414A
26
JP2006137765A
26
JP2006514917A
62
JP2007505906A
51
JP2009137975A
26
JP2009513190A
32
JP2011508747A
62
JP2011526302A
67
JPH06189748A
26
JPH06199887A
26
JPH07247299A
26
JPH07278177A
26
JPH1072457A
26
JPH11322777A
26
JPS05785319A
26
JPS56125382A
26
JPS56147798A
26
JPS58159500A
26
JPS61291516A
32
JPS62115299A
26
JPS62294623A
35
JPS6287599A
26
JPS6423A
26
JPS6466122A
26
US20140128583
26
US2653899
26
US4219641
26
US5118799
26

Sample Use Guides

In Vivo Use Guide
The usual dosage of erythromycin tablets is one 250 mg tablet four times daily in equally spaced doses or one 500 mg tablet every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.
Route of Administration: Oral
In Vitro Use Guide
The MIC values for erythromycin were: 0.25-1 ug/ml (Staphylococcus aureus ATCC 29213), 1-4 ug/ml (Enterococcus faecalis ATCC 29212), 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:52:46 GMT 2025
Edited
by admin
on Mon Mar 31 17:52:46 GMT 2025
Record UNII
JVF6FH67JR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERYTHROMYCIN, MONOHYDRIODIDE, MONOHYDRATE
Preferred Name English
ERYTHROMYCIN HYDRIODIDE MONOHYDRATE
Common Name English
Code System Code Type Description
PUBCHEM
133082255
Created by admin on Mon Mar 31 17:52:46 GMT 2025 , Edited by admin on Mon Mar 31 17:52:46 GMT 2025
PRIMARY
CAS
65945-11-1
Created by admin on Mon Mar 31 17:52:46 GMT 2025 , Edited by admin on Mon Mar 31 17:52:46 GMT 2025
NON-SPECIFIC STOICHIOMETRY
FDA UNII
JVF6FH67JR
Created by admin on Mon Mar 31 17:52:46 GMT 2025 , Edited by admin on Mon Mar 31 17:52:46 GMT 2025
PRIMARY
CAS
14550-96-0
Created by admin on Mon Mar 31 17:52:46 GMT 2025 , Edited by admin on Mon Mar 31 17:52:46 GMT 2025
PRIMARY
Related Record Type Details
Structure of Erythromycin
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of Erythromycin
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966